Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 409-415

  Sukru Aynacioglu A ^a,b   Brockmöller, Jürgen ^a   Bauer, Steffen ^a   Sachse, Christoph ^a   Güzelbey, Pinar ^b   Öngen, Zuhal ^b   Nacak, Muradiye ^b   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

CYP2C9; Cytochrome P450 2C9; Pharmacogenetics; Phenytoin; Turkey

Indexed keywords

CYSTEINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; LEUCINE; PHENYTOIN;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT; TURKEY (REPUBLIC);

EID: 0032819729     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00012.x     Document Type: Article

References (23)

1. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
2. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998; 28: 1-13.
3. Bhasker CR, Minces JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7: 51-58.
4. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533-538.
5. Furuya H, Fernandez Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on wafarin maintenance dose requirement in patients undergoing anticoagultation therapy. Pharmacogenetics 1995; 5: 389-392.
6. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7: 361-367.
7. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-528.
8. Yamazaki H, Inoue K, Shimada T. Roles of two allelic variants (Arg144Cys and He359Lcu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 1998; 28: 103-115.
9. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′ hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997; 7: 103-113.
10. Kumar GN, Dubberke E, Rodrigues AD, Roberts E, Dennisen JF, Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor scratrodast (ABT-001). Drug Metab Dispos 1997; 25: 110-115.
11. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-299.
12. Kalow W. Interethnic variation of drag metabolism. Trends Pharmacol Sci 1991; 12: 102-107.
13. Idle JR, Sloan TP, Smith RI, Wakile LA. Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings]. Br J Pharmacol 1979; 66: 430P-431P.
14. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Chin Pharmacol Ther 1990; 47: 403-411.
15. Dickinson RG, Hooper WD, Patterson M, Eadie MJ, Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 1985; 7: 283-289.
16. Brockmöller J, Rost KI, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G→A-splice site mutation. Pharmacogenetics 1995; 5: 80-88.
17. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996; 6: 527-533.
18. Ackermann E, Cascorbi I, Sachse C, Brockmöller J, Roots I. A novel CYP2C9 intron 2 T/C transition and linkage of mutations Cys144 and Leu359. 12th International Symposium on Microsomes and Drug Oxidations 1998 Montpellier, France.
19. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
20. Haining RL, Hunter AP, Veronese ME, Trager WI, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys 1996; 333: 447-458.
21. Spielberg S, McCrea J, Cribb A, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. 97th Annual Meeting of the American Society for Chinical Pharmacology and Therapeutics 1996 Florida, USA.
22. Fritz S, Lindner W, Roots I, Frey BM, Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987; 241: 615-622.
23. Ieiri I, Goto W, Hirata K, et at. Effect of 5 (p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic gingival hyperplasia: In vivo and in vitro study. Eur J Clin Pharmacol 1995; 49: 51-56.